Novavax Inc. filings document formal disclosures for a Nasdaq-listed biotechnology company focused on vaccine products, Matrix-M adjuvant technology and partnership-driven development. Recent 8-K reports record operating results, preliminary financial information, licensing arrangements for Matrix-M, Nuvaxovid marketing-authorization transfers, and facility-related agreements.
Proxy materials describe board matters, executive compensation, equity awards, shareholder voting items and governance procedures. The filings also identify Novavax common stock, par value $0.01 per share, as listed on The Nasdaq Global Select Market under NVAX.
Novavax, Inc. filed its annual report describing a vaccine-focused business built on its protein-based nanoparticle platform and Matrix-M™ adjuvant, used in its Nuvaxovid COVID‑19 vaccine and the R21/Matrix‑M malaria vaccine. The company emphasizes partnerships and a lean operating model to fund ongoing R&D.
Key commercial moves include a global collaboration with Sanofi, which triggered a $175 million milestone upon FDA approval of Nuvaxovid’s BLA and will eventually shift COVID‑19 commercialization to Sanofi, plus future milestone and royalty potential on COVID‑19, COVID‑influenza combination, and other adjuvanted products. Novavax also signed a non‑exclusive Matrix‑M license with Pfizer including a $30 million upfront payment and up to $500 million in milestones, and amended its agreement with Takeda in Japan to a royalty-based structure.
The company continues to unwind legacy COVID‑19 supply contracts. It recognized $575.7 million of product sales after Canada terminated its APA, while refunding $28.0 million, and recorded $27.3 million of product sales following a settlement with New Zealand. Remaining advance purchase obligations total about $0.4 billion, including $133.9 million with Australia and $225.0 million with Gavi, with portions potentially refundable if regulatory or supply conditions are not met. As of June 30, 2025, non‑affiliate equity market value was approximately $1.018 billion, and there were 162,935,945 shares outstanding as of February 16, 2026.
Novavax, Inc. filed its annual report describing a vaccine-focused business built on its protein-based nanoparticle platform and Matrix-M™ adjuvant, used in its Nuvaxovid COVID‑19 vaccine and the R21/Matrix‑M malaria vaccine. The company emphasizes partnerships and a lean operating model to fund ongoing R&D.
Key commercial moves include a global collaboration with Sanofi, which triggered a $175 million milestone upon FDA approval of Nuvaxovid’s BLA and will eventually shift COVID‑19 commercialization to Sanofi, plus future milestone and royalty potential on COVID‑19, COVID‑influenza combination, and other adjuvanted products. Novavax also signed a non‑exclusive Matrix‑M license with Pfizer including a $30 million upfront payment and up to $500 million in milestones, and amended its agreement with Takeda in Japan to a royalty-based structure.
The company continues to unwind legacy COVID‑19 supply contracts. It recognized $575.7 million of product sales after Canada terminated its APA, while refunding $28.0 million, and recorded $27.3 million of product sales following a settlement with New Zealand. Remaining advance purchase obligations total about $0.4 billion, including $133.9 million with Australia and $225.0 million with Gavi, with portions potentially refundable if regulatory or supply conditions are not met. As of June 30, 2025, non‑affiliate equity market value was approximately $1.018 billion, and there were 162,935,945 shares outstanding as of February 16, 2026.
Bank of America Corporation has disclosed beneficial ownership of 8,315,530 shares of Novavax, Inc. common stock, representing 5.1% of the outstanding class as of the date used in the calculation. Most shares carry shared voting and dispositive power, with no sole authority reported.
The filing states these securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Novavax. The position is held across Bank of America and wholly owned subsidiaries, including broker-dealer and banking entities.
State Street Corporation reports beneficial ownership of 9,523,646 shares of Novavax, Inc. common stock, representing 5.9% of the class as of 12/31/2025. All voting and dispositive authority is described as shared, with no sole power reported.
The filing lists several affiliated asset management subsidiaries, including SSGA Funds Management and State Street Global Advisors entities, as the investment managers involved. State Street certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Novavax.
Novavax President and CEO John C. Jacobs reported equity transactions in Novavax, Inc. common stock. On January 23, 2026, he converted 83,197 Restricted Stock Units (RSUs) into an equal number of common shares at an exercise price of $0, increasing his directly held common stock to 219,929 shares. On the same date, he executed a transaction coded F involving 39,132 common shares at $9.17 per share, after which he directly beneficially owned 180,797 shares of Novavax common stock. The footnote explains that one-third of the RSUs from this grant vest on each of the first three anniversaries of the grant date, conditioned on continued employment.
Novavax entered a worldwide, non-exclusive license and option agreement with Pfizer covering its Matrix-MTM adjuvant technology for vaccine products in at least one and up to two infectious disease areas. Pfizer will lead development, manufacturing, and commercialization of any licensed products, while Novavax will handle adjuvant supply under separate agreements.
Novavax will receive an upfront payment of $30 million in the first quarter of 2026 and is eligible for up to $500 million in additional milestones. These include up to $70 million in development milestones and up to $180 million in sales milestones for each of the First and potential Second Fields. Novavax is also eligible for tiered high mid-single digit percentage royalties on Pfizer’s quarterly net sales, with royalties lasting at least twenty years from first commercial sale or while valid patents remain. The company states that, assuming Pfizer commercializes a product in the First Field, the arrangement has the potential to generate billions of dollars of revenue over the life of the agreement.
Novavax, Inc. filed a Form 8-K stating that on January 12, 2026 it plans to provide an investor update, including preliminary financial data for the year ended December 31, 2025. Management is still finalizing these results, and the figures discussed are preliminary, unaudited and may change, potentially in a material way.
The company notes that its independent registered public accounting firm, Ernst & Young LLP, has not audited, reviewed, compiled or performed any procedures on this preliminary information and does not give any assurance on it. Novavax also highlights that additional material information will appear in its full 2025 financial statements prepared under U.S. GAAP.
At the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, Novavax will present strategic and business updates in an Investor Presentation furnished as Exhibit 99.1 and posted on its website. The 8-K and the presentation contain forward-looking statements, including expectations for combined annual research and development and selling, general and administrative expenses for 2025, 2026 and 2027, all subject to significant risks and uncertainties.
Novavax’s executive vice president and chief legal officer reported equity award activity involving company stock. On 12/11/2025, the executive acquired 41,899 shares of Novavax common stock at $0 per share, increasing direct ownership to 73,972 shares immediately after that transaction.
On the same date, a separate transaction coded “F” shows the disposition of 12,713 shares at a price of $6.69 per share, leaving the executive with 61,159 shares of common stock held directly. The filing also lists 41,899 restricted stock units tied to Novavax common stock at a $0 exercise price, with a vesting schedule under which one-third of the RSUs vest on each of the first three anniversaries of the grant date, subject to continued employment.
Novavax (NVAX) officer reported equity transactions on 11/11/2025. 14,257 shares of common stock were acquired at $0.00 via RSU conversion (Code M), and 6,048 shares were sold to cover taxes at $7.40 (Code F). After these transactions, 8,209 common shares were held directly.
The filing lists RSU activity tied to these shares and shows 28,513 restricted stock units beneficially owned following the transactions. Each RSU represents one share, with vesting at one‑third on each of the first three anniversaries of the grant date, subject to continued employment.
Novavax, Inc. (NVAX) reported an update on results. The company furnished an 8-K stating it issued a press release with its financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1. This filing formally notifies the market of the availability of the company’s Third Quarter financial information.
Novavax (NVAX) filed its Q3 2025 10‑Q, reporting total revenue of $70.4 million driven by licensing and services to partners, while recording a net loss of $202.4 million. Product sales were $13.4 million and licensing, royalties, and other revenue was $57.0 million.
Operating results reflected an $97.0 million impairment on assets held for sale and a loss on debt extinguishment of $28.7 million tied to exchanging 2027 notes for new 2031 notes. For the first nine months of 2025, revenue reached $976.3 million and net income was $422.8 million, aided by recognition of amounts previously in deferred revenue following the Canada APA termination.
Cash and cash equivalents were $268.0 million with marketable securities of $494.9 million as of September 30, 2025, and the company concluded it has sufficient capital for the one‑year look‑forward period. Collaboration activity remained significant: Sanofi-related revenue included $4.2 million royalties in Q3 and previously achieved milestones of $175 million (U.S. BLA approval). The Australia APA includes potential refundable amounts of up to $92.5 million if regulatory approvals and deliveries are not met by specified dates.